FDA Finalizes Guidance for Prescription Drug Companion Apps and Software

The U.S. Food and Drug Administration (FDA) has issued final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines. This guidance clarifies when app content requires FDA review, when an app should be mentioned on a drug's official label, and what companies should submit to the agency. The policy aims to reduce regulatory uncertainty for drugmakers and technology developers while maintaining safety and effectiveness standards for these tools, which are increasingly used by patients to manage medications and health conditions.